POM-V Prescription Required Companion Animal

Kelactin 50 Microgram/ml Oral Solution for Dogs and Cats

Active ingredient: Cabergoline

Form

Liquid

Species

Cats Dogs

Manufacturer

Veyx-Pharma GmbH

VMD MA No.

27569/4008

What it's used for

The veterinary medicinal product is indicated for the following uses: - -

Full indications, dosage and side effects ↓

View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Cabergoline

1

Ask your vet for a written prescription

They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
2

Fill it at a registered online retailer

The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Your prescription rights → VMD register of retailers →

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

Kelactin 50 Microgram/ml Oral Solution for Dogs and Cats — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 26 Mar 2026.

The veterinary medicinal product is indicated for the following uses:
-
-

The veterinary medicinal product should be administered orally either directly into the
mouth or by mixing with food.
The dosage is 0.1 ml/kg bodyweight (equivalent to 5 microgram/kg bodyweight of
cabergoline) once daily for 4-6 consecutive days, depending on the severity of the
clinical condition.
If the signs fail to resolve after a single course of treatment, or if they recur after the
end of treatment, then the course of treatment may be repeated.
The weight of treated animal should be accurately determined before administration.
How to withdraw the recommended volume from the vial ?
It is recommended to use the vial adapter and syringe included in the packaging to
withdraw the veterinary medicinal product from the vial. For that the following steps
are necessary:
Preparing the vial for first use:
Place the vial on a flat surface. Place the adapter straight from above on the vial, so
that the pin of the adapter pierces the stopper in center position. Fix the adapter
tightly on the vial by pushing down.
The adapter now permanently remains on the vial. It seals the vial tightly and keeps
the product ready for use until emptying.

Revised: September 2023
AN: 03785/2022 & 03794/2022
Withdrawal of the required/prescribed amount:
a. Attach the syringe to the adapter by firmly pressing the syringe into the vial
adapter, thus to avoid leaking of the product when withdrawing the dose from the
vial.
b. Withdraw the drug from the vial into the syringe holding the vial upside down.
c. Remove the syringe from the adapter in upright position. Leave the adapter on
the vial.
d. The drug is now ready for administration.
It is recommended to rinse and dry the syringe following each application. For the
next withdrawal, start with step a.
a. b. c. d.

-
-
-
excipients.
Cabergoline may induce transient hypotension in treated animals. Do not use in
animals concurrently being treated with hypotensive drugs. Do not use directly after
surgery whilst the animal is still under the influence of the anaesthetic agents.

Revised: September 2023
AN: 03785/2022 & 03794/2022

Possible adverse effects are:
-
-
-
These adverse effects are usually of a moderate and transient nature.
Vomiting usually only occurs after the first administration. In this case treatment
should not be stopped, since the vomiting will not reoccur after the following
administrations.
In very rare cases allergic reactions may occur, such as oedema, urticaria, dermatitis
and pruritus.
In very rare cases a transient hypotension may occur.
In very rare cases neurological symptoms may occur, such as sleepiness, muscle
tremor, ataxia, hyperactivity and convulsions.
The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals displaying adverse reactions during the
course of one treatment)
- common (more than 1 but less than 10 animals in 100 animals)
- uncommon (more than 1 but less than 10 animals in 1,000 animals)
- rare (more than 1 but less than 10 animals in 10,000 animals)
- very rare (less than 1 animal in 10,000 animals, including isolated reports).

Revised: September 2023
AN: 03785/2022 & 03794/2022

Additional supportive treatments should involve restriction of water and carbohydrate
intake and increase exercise.

i) Special precautions for use in animals
Not applicable.
(ii) Special precautions to be taken by the person administering the veterinary
medicinal product to animals
Wash hands after use. Avoid contact with skin and eyes. Wash off any splashes
immediately.
Women of childbearing potential and breast-feeding woman should not handle the
product or should wear disposable gloves when administering the product.
People with known hypersensitivity to cabergoline or any of the other ingredients in
the product should avoid contact with the veterinary medicinal product.
Do not leave unattended filled syringes in presence of children. In the event of
accidental ingestion, particularly by a child, seek medical attention immediately and
show the package leaflet or the label to the physician.

Since cabergoline exerts its therapeutic effect by direct stimulation of dopamine
receptors, the product should not be administered concurrently with drugs which
have dopamine antagonist activity (such as phenothiazines, butyrophenones,
metoclopramide), as these might reduce its prolactin inhibiting effects.
Since cabergoline may induce transient hypotension, the product should not be used
in animals concurrently treated with hypotensive drugs.

As packaged for sale: store in a refrigerator (2°C - 8°C).
After first opening: store below 25°C.
Store in upright position.
Keep the vial tightly closed in the outer carton in order to protect from light.
Do not freeze.

Revised: September 2023
AN: 03785/2022 & 03794/2022

Not applicable.
5.

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.